Home › Compare › BBIXF vs ORCC

BBIXF vs ORCC: Dividend Comparison 2026

BBIXF yields 1666.67% · ORCC yields 9.79%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 BBIXF wins by $1839785666.24M in total portfolio value
10 years
BBIXF
BBIXF
● Live price
1666.67%
Share price
$0.12
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$1839785666.26M
Annual income
$1,645,561,548,268,653.00
Full BBIXF calculator →
ORCC
ORCC
● Live price
9.79%
Share price
$13.48
Annual div
$1.32
5Y div CAGR
-50%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$21.4K
Annual income
$1.04
Full ORCC calculator →

Portfolio growth — BBIXF vs ORCC

📍 BBIXF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodBBIXFORCC
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, BBIXF + ORCC cover 0 of 12 months — good coverage

Jan
—
Feb
—
Mar
—
Apr
—
May
—
Jun
—
Jul
—
Aug
—
Sep
—
Oct
—
Nov
—
Dec
—
BBIXF pays
ORCC pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

BBIXF
Annual income on $10K today (after 15% tax)
$141,666.67/yr
After 10yr DRIP, annual income (after tax)
$1,398,727,316,028,355.00/yr
ORCC
Annual income on $10K today (after 15% tax)
$832.34/yr
After 10yr DRIP, annual income (after tax)
$0.88/yr
At 15% tax rate, BBIXF beats the other by $1,398,727,316,028,354.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of BBIXF + ORCC for your $10,000?

BBIXF: 50%ORCC: 50%
100% ORCC50/50100% BBIXF
Portfolio after 10yr
$919892833.14M
Annual income
$822,780,774,134,327.00/yr
Blended yield
89.44%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ORCC right now

BBIXF
No analyst data
Altman Z
-19.8
Piotroski
2/9
ORCC
Analyst Ratings
9
Buy
4
Hold
1
Sell
Consensus: Buy
Price Target
$16.00
+18.7% upside vs current
Range: $16.00 — $16.00
Altman Z
0.5
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

BBIXF buys
0
ORCC buys
0
No recent congressional trades found for BBIXF or ORCC in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricBBIXFORCC
Forward yield1666.67% ✓9.79%
Annual dividend / share$2.00 ✓$1.32
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0% ✓-50%
Portfolio after 10y$1839785666.26M ✓$21.4K
Annual income after 10y$1,645,561,548,268,653.00 ✓$1.04
Total dividends collected$1825787439.21M ✓$1.0K
Payment frequencyquarterlyquarterly
SectorStockBDC

Year-by-year: BBIXF vs ORCC ($10,000, DRIP)

YearBBIXF PortfolioBBIXF Income/yrORCC PortfolioORCC Income/yrGap
1← crossover$177,367$166,666.67$11,190$489.61+$166.2K → BBIXF
2$2,952,503$2,762,720.66$12,229$256.01+$2.94M → BBIXF
3$46,139,686$42,980,507.73$13,216$130.74+$46.13M → BBIXF
4$677,098,258$627,728,794.51$14,207$66.02+$677.08M → BBIXF
5$9,333,745,461$8,609,250,324.41$15,234$33.17+$9333.73M → BBIXF
6$120,900,966,251$110,913,858,608.07$16,317$16.62+$120900.95M → BBIXF
7$1,472,054,345,780$1,342,690,311,890.92$17,468$8.32+$1472054.33M → BBIXF
8$16,853,789,214,559$15,278,691,064,574.45$18,695$4.16+$16853789.20M → BBIXF
9$181,517,867,281,133$163,484,312,821,554.84$20,006$2.08+$181517867.26M → BBIXF
10$1,839,785,666,259,465$1,645,561,548,268,653.00$21,407$1.04+$1839785666.24M → BBIXF

BBIXF vs ORCC: Complete Analysis 2026

BBIXF — Stock

Bonus BioGroup Ltd., a biotechnology company, develops technology solutions to generate tissue-regenerating bone grafts. It develops tissue-regenerating bone grafts from cells derived from the patient's own cells for the treatment of skeletal disorders, such as bone trauma and arthritis. The company's products include BonoFill injectable bone graft that is suitable for bone repair applications, including jaw bone cysts; and BonoFill pre-designed bone graft, which is used to repair large and segmental bone defects. Its products in pipeline comprise bone grafts for maxillofacial and orthopedic applications; novel nanomaterials technology for tissue regeneration; and large vascularized bone grafts. The company was formerly known as Oceana Advanced Industries Ltd. and changed its name to Bonus BioGroup Ltd. Bonus BioGroup Ltd. was founded in 1981 and is based in Haifa, Israel.

Full BBIXF Calculator →

ORCC — BDC

Owl Rock Capital Corporation is a business development company. The fund makes investments in senior secured or unsecured loans, subordinated loans or mezzanine loans and also considers equity-related securities including warrants and preferred stocks also pursues preferred equity investments and common equity investments. Within private equity, it seeks to invest in growth, acquisitions, market or product expansion, refinancings and recapitalizations. It seeks to invest in middle market companies based in the United States, with EBITDA between $10 million and $250 million annually and/or annual revenue of $50 million and $2.5 billion at the time of investment.

Full ORCC Calculator →
📬

Get this BBIXF vs ORCC comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

BBIXF vs SCHDBBIXF vs JEPIBBIXF vs OBBIXF vs KOBBIXF vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.